Full Text | PDF

Share on tweeters Share on facebook Share on linkedin Share on googleplus

J Cancer 2024; 15(6):1750-1761. doi:10.7150/jca.91089 This issue Cite

Research Paper

Dual Inhibition of B7-H3 and EGFR Overcomes Acquired Chemoresistance in Colon Adenocarcinoma

Liang-Chi Chen1,*, Pei-Chen Yang2,*, Chia-Yi Chen2, Shu-Fen Chiang3, Tsung-Wei Chen4, William Tzu-Liang Chen5,6,7, Tao-Wei Ke6,8, Ji-An Liang9,10, An‑Cheng Shiau9,11, K. S. Clifford Chao2,9,10, Kevin Chih-Yang Huang11,12,13✉

1. Department of Pathology, China Medical University Hospital, China Medical University, Taichung 40402, Taiwan.
2. Proton Therapy and Science Center, China Medical University Hospital, China Medical University, Taichung 40402, Taiwan.
3. Lab of Precision Medicine, Feng-Yuan Hospital, Ministry of Health and Welfare, Taichung 42055, Taiwan.
4. Department of Pathology, Asia University Hospital, Asia University, Taichung 41354, Taiwan.
5. Department of Colorectal Surgery, China Medical University HsinChu Hospital, China Medical University, HsinChu 302, Taiwan.
6. Department of Colorectal Surgery, China Medical University Hospital, China Medical University, Taichung 40402, Taiwan.
7. Department of Surgery, School of Medicine, China Medical University, Taichung 40402, Taiwan.
8. School of Chinese Medicine, China Medical University, Taichung 40402, Taiwan.
9. Department of Radiation Oncology, China Medical University Hospital, China Medical University, Taichung, Taiwan.
10. Department of Radiotherapy, School of Medicine, China Medical University, Taichung 40402, Taiwan.
11. Department of Biomedical Imaging and Radiological Science, China Medical University, Taichung 40402, Taiwan.
12. Translation Research Core, China Medical University Hospital, China Medical University, Taichung 40402, Taiwan.
13. Cancer Biology and Precision Therapeutics Center, China Medical University, Taichung 40402, Taiwan.
* These authors have contributed equally to this work and share first authorship.

✉ Corresponding author: Prof. Kevin Chih-Yang Huang, Department of Biomedical Imaging and Radiological Science, China Medical University, E-mail: chihyang0425cmu.edu.tw.

Citation:
Chen LC, Yang PC, Chen CY, Chiang SF, Chen TW, Chen WTL, Ke TW, Liang JA, Shiau A, Chao KSC, Huang KCY. Dual Inhibition of B7-H3 and EGFR Overcomes Acquired Chemoresistance in Colon Adenocarcinoma. J Cancer 2024; 15(6):1750-1761. doi:10.7150/jca.91089. https://www.jcancer.org/v15p1750.htm
Other styles

File import instruction

Abstract

Graphic abstract

Despite advances in therapeutic strategies for colorectal cancer (CRC), CRC has a high disease incidence with significant morbidity and mortality worldwide. Notably, immunotherapy has shown limited efficacy in treating metastatic CRC, underscoring the need for alternative immunotherapeutic targets for the management of metastatic colorectal cancer (mCRC). In the present study, we evaluated the levels of the immune checkpoint proteins PD-L1, PD-L2 and B7-H3 in a large cohort retrospective study. We found that tumor B7-H3 (52.7%) was highly expressed in primary tumors compared to that in PD-L1 (33.6%) or PD-L2 (34.0%). Elevated B7-H3 expression was associated with advanced stage and the risk of distant metastasis and correlated with poor disease-free survival (DFS), suggesting that tumor B7-H3 was an independent prognostic factor associated with worse DFS in colon adenocarcinoma patients (COAD), especially high-risk COAD patients who received adjuvant chemotherapy. Furthermore, we found that B7-H3 significantly promoted cell proliferation and tumor growth in CRC. B7-H3 may stabilize EGFR to activate its downstream pathway for cancer cell proliferation and resistance to oxaliplatin (OXP). Dual targeting of B7-H3 and EGFR markedly rescued the susceptibility to chemotherapy in colorectal cancer cells in vitro and in vivo. Overall, these results showed that B7-H3 exhibited a high prevalence in COAD patients and was significantly associated with worse prognosis in COAD patients. Dual targeting of B7-H3 and EGFR signaling might be a potential therapeutic strategy for high-risk COAD patients.

Keywords: Colorectal cancer, B7-H3, Intratumoral infiltrating lymphocytes, PD-L1

Citation styles

APA
Chen, L.C., Yang, P.C., Chen, C.Y., Chiang, S.F., Chen, T.W., Chen, W.T.L., Ke, T.W., Liang, J.A., Shiau, A., Chao, K.S.C., Huang, K.C.Y. (2024). Dual Inhibition of B7-H3 and EGFR Overcomes Acquired Chemoresistance in Colon Adenocarcinoma. Journal of Cancer, 15(6), 1750-1761. https://doi.org/10.7150/jca.91089.

ACS
Chen, L.C.; Yang, P.C.; Chen, C.Y.; Chiang, S.F.; Chen, T.W.; Chen, W.T.L.; Ke, T.W.; Liang, J.A.; Shiau, A.; Chao, K.S.C.; Huang, K.C.Y. Dual Inhibition of B7-H3 and EGFR Overcomes Acquired Chemoresistance in Colon Adenocarcinoma. J. Cancer 2024, 15 (6), 1750-1761. DOI: 10.7150/jca.91089.

NLM
Chen LC, Yang PC, Chen CY, Chiang SF, Chen TW, Chen WTL, Ke TW, Liang JA, Shiau A, Chao KSC, Huang KCY. Dual Inhibition of B7-H3 and EGFR Overcomes Acquired Chemoresistance in Colon Adenocarcinoma. J Cancer 2024; 15(6):1750-1761. doi:10.7150/jca.91089. https://www.jcancer.org/v15p1750.htm

CSE
Chen LC, Yang PC, Chen CY, Chiang SF, Chen TW, Chen WTL, Ke TW, Liang JA, Shiau A, Chao KSC, Huang KCY. 2024. Dual Inhibition of B7-H3 and EGFR Overcomes Acquired Chemoresistance in Colon Adenocarcinoma. J Cancer. 15(6):1750-1761.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image

©2024 Ivyspring International Publisher. Terms of use